Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Nest Genomics
Study ID
NCT06654466
Status
Recruiting
Apply to this trial

Conditions

  • Clinical Decision Support
  • Hereditary Cancer Syndromes

Eligibility Criteria

Sex
ALL
Age
18 Years - 49 Years
Healthy Volunteers
Not accepted

Interventions

  • Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale. — DEVICE
    The Nest software platform includes the Nest Care Studio, Nest Patient Navigator and the Analytics Dashboard. Nest Care Studio is a clinician facing portal that can be used standalone or electronic medical record (EMR) integrated. Care Studio enables clinicians to effectively manage patients' genetic information over time. Clinicians can see a list of patients that meet criteria for testing, run risk assessment calculations, order genetic tests, manage patients based on results and view education modules.The Nest Patient Navigator is a secure mobile device accessible platform that provides a centralized location for patients to store, manage, and follow-up with their genetic results. The Analytics Dashboard is an interactive dashboard that can track outcomes of genomic programs and trigger interventions to optimize them.

Study Details

The goal of this clinical trial is to see if a software platform can improve cancer screening in young adults with genetic risk for cancer. The trial will also help improve the software platform (Nest). The main questions it aims to answer are: * Do Nest users know more about their cancer risks and recommended care than non-users? * Do Nest users have less psychological distress than non-users? * Do Nest users share cancer risks with family and other doctors more than non-users? * Are Nest users more likely than non-users to have up-to-date care plans? Researchers will compare Nest users to non-users to see if the Nest users are more likely to do recommended cancer screening. Participants will: * Have a genetic counseling or follow up visit * Take a post-visit survey * Intervention arm only: use the Nest Patient Navigator * Complete screening and follow-up care recommended by doctors

Key Dates

Start date
Feb 10, 2026
Status verified
Dec 2025
Primary completion
Mar 31, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • No Intervention: Control Arm
    Patients in the control arm will complete a standard genetic counseling or follow-up visit and a post-visit survey.
  • Experimental: Intervention Arm
    Patients in the intervention arm will complete a genetic counseling or follow-up visit with a clinician using Nest Clinical Decision Support and a post visit-survey. Intervention arm patients will be given access to the Nest Patient Navigator.

Primary Outcome Measure

Acceptability of Intervention Measure (AIM) [ Time Frame: within 7 days of visit ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dana Farber Cancer InstituteBostonMassachusetts02215-

Find similar trials in Boston, MA

By research site
Dana Farber Cancer Institute· Boston, MA

Related Studies